Ctl019 | search
Click here to view Ctl019 news from 60+ newspapers.
Bookmark or Share- Tisagenlecleucel - WikipediaCAS Number. 1823078-37-0. DrugBank. DB13881. UNII. Q6C9WHR03O. KEGG. D11386. Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer ( adoptive cell transfer ).
- A safe and potent anti-CD19 CAR T cell therapy | Nature MedicineCTL019 and other anti-CD19 CAR T cells are effective in the treatment of relapsed or refractory B cell lymphoma and leukemia, but they often cause severe toxicities, including CRS and neurological ...
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell ...Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood ...
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic ...Tisagenlecleucel (formerly CTL019), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is under investigation in patients with relapsed or refractory B-cell cancers, including B-cell ...
- CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B ...Abstract. Over the past decades, survival of patients with acute lymphoblastic leukemia (ALL) has dramatically improved, but the subgroup of patients with relapsed/refractory ALL still continues to have dismal prognosis. As an emerging therapeutic approach, chimeric antigen receptor-modified T-cells (CAR-T) represent one of the few practice ...
More
